Comprehensive medication guide to Actemra including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0 per treatment for commercially insured patients enrolled in the Actemra Co-pay Program; without assistance, specialty tier cost-sharing typically ranges from $100–$500+ per infusion or injection depending on deductible and coinsurance; biosimilar versions (Tyenne, Avtozma) may be placed on lower-cost preferred tiers by many plans.
Estimated Cash Pricing
$2,308–$4,616 per month for IV formulations and $2,478–$4,956 per month for subcutaneous formulations at retail list price; commercially insured patients may pay as little as $0 per treatment with the Genentech Actemra Co-pay Program (up to $15,000/year savings).
Medfinder Findability Score
65/100
On this page
Actemra is the brand name for tocilizumab, a biologic medication manufactured by Genentech (a member of the Roche Group). It belongs to a class of drugs called interleukin-6 (IL-6) receptor antagonists — humanized monoclonal antibodies that target a specific protein in the immune system responsible for driving chronic inflammation.
Actemra has seven FDA-approved indications: moderate-to-severe rheumatoid arthritis (RA) in adults, giant cell arteritis (GCA) in adults, systemic sclerosis-associated interstitial lung disease (SSc-ILD), polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years and older, systemic juvenile idiopathic arthritis (SJIA), cytokine release syndrome (CRS) from CAR-T cell therapy, and COVID-19 in hospitalized patients requiring oxygen support.
As of 2026, three FDA-approved biosimilars are available: Tofidence (tocilizumab-bavi, Biogen), Tyenne (tocilizumab-aazg, Fresenius Kabi), and Avtozma (tocilizumab-anoh, Celltrion). These biosimilars are therapeutically equivalent to brand Actemra and are available in IV and/or SC formulations.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Actemra works by blocking the interleukin-6 (IL-6) receptor. IL-6 is a signaling protein (cytokine) that plays a central role in driving inflammation throughout the body. In autoimmune diseases like rheumatoid arthritis, IL-6 is chronically overproduced, causing persistent joint inflammation, pain, swelling, and tissue damage.
As a humanized monoclonal antibody, tocilizumab binds to both membrane-bound and soluble IL-6 receptors, preventing IL-6 from attaching and transmitting its inflammatory signal. This broad inhibition reduces the production of acute-phase proteins (like CRP), decreases immune cell activation, and lowers systemic and joint inflammation.
In cytokine release syndrome (CRS) — a life-threatening condition triggered by CAR-T cell therapy or severe COVID-19 — IL-6 is massively overproduced, leading to a "cytokine storm." Actemra rapidly dampens this dangerous immune overreaction by blocking IL-6 signaling, which reduces organ-threatening inflammation and improves survival rates.
80 mg/4 mL (IV) — intravenous solution
Single-dose vial for IV infusion administered in clinical setting
200 mg/10 mL (IV) — intravenous solution
Single-dose vial for IV infusion administered in clinical setting
400 mg/20 mL (IV) — intravenous solution
Single-dose vial for IV infusion administered in clinical setting
162 mg/0.9 mL (SC) — subcutaneous prefilled syringe
Self-injected at home; weekly or every other week based on weight and condition
162 mg/0.9 mL (SC) — subcutaneous ACTPen autoinjector
Self-injected at home using autoinjector device; same dosing as prefilled syringe
Actemra's availability has improved significantly since the acute shortage of 2021, when COVID-19 demand caused a nationwide depletion of all IV formulations. By 2022, Genentech restored stable supply, and the entry of three biosimilars (2023–2026) has expanded the total tocilizumab supply pool. We rate Actemra's current findability at 65/100 — generally available, but with meaningful hurdles.
Key findability factors: Actemra IV is only dispensed through infusion centers and clinical settings, not retail pharmacies. Actemra SC is distributed through specialty pharmacies, not standard chains. Insurance step therapy requirements can delay access to brand Actemra even when it's in stock. The American College of Rheumatology has noted regional supply constraints for the Tyenne biosimilar, demonstrating that localized gaps still occur.
If you're struggling to find Actemra in stock, medfinder is a paid service that calls specialty pharmacies near you to check which ones can fill your prescription — saving you hours of phone calls and hold time.
Actemra is not a controlled substance, so there are no DEA prescribing restrictions. However, because it is a complex biologic requiring TB screening, baseline labs, and regular monitoring, it is almost exclusively prescribed and managed by specialists. Most insurance plans require specialty prescriber documentation for prior authorization approval.
Telehealth rheumatologists can prescribe Actemra SC for established patients with confirmed diagnoses. Initial diagnosis typically requires an in-person evaluation including joint assessment and laboratory testing. The IV formulation always requires in-person administration at an infusion center or clinical setting, regardless of how the prescription is generated.
No. Actemra (tocilizumab) is not a controlled substance and has no DEA scheduling. It does not have any restrictions on prescription quantities or refill limits based on controlled substance law.
However, Actemra does require a prescription from a licensed prescriber, and insurance coverage almost always requires prior authorization. Many payers also impose step therapy requirements, meaning patients may need to try a preferred biosimilar (such as Tyenne or Avtozma) before the insurer will cover brand-name Actemra. These access barriers are administrative and financial — not regulatory controlled substance restrictions.
The most commonly reported side effects of Actemra include:
Know what you need? Skip the search.
Sarilumab (Kevzara)
Only other FDA-approved IL-6 receptor antagonist for RA. Subcutaneous only. Similar mechanism to Actemra but not approved for GCA, SSc-ILD, JIA, or CRS.
Baricitinib (Olumiant)
Oral JAK1/2 inhibitor approved for RA, alopecia areata, and atopic dermatitis. Once daily pill — no injections required. Different mechanism of action.
Upadacitinib (Rinvoq)
Oral JAK1 inhibitor approved for RA and several other conditions. Once daily pill. Higher efficacy data than some biologics in certain patient populations.
Adalimumab (Humira)
TNF inhibitor and one of the most prescribed biologics for RA. Many biosimilars available. Different mechanism (blocks TNF-alpha rather than IL-6).
Prefer Actemra? We can find it.
Abatacept (Orencia)
majorCombination is contraindicated — increased immunosuppression and serious infection risk.
TNF inhibitors (Humira, Enbrel, Remicade, etc.)
majorAvoid concurrent use — compounded immunosuppression significantly increases serious infection risk.
JAK inhibitors (baricitinib, tofacitinib, upadacitinib)
majorCombination not recommended — additive immunosuppression.
Live vaccines
majorDo not give live vaccines while on Actemra — immunosuppression may allow vaccine virus to cause active infection.
Warfarin (Coumadin)
moderateActemra can alter CYP3A4 activity, affecting warfarin metabolism. Monitor INR closely when starting or stopping.
Statins (atorvastatin, lovastatin, simvastatin)
moderateIncreased CYP3A4 activity may lower statin blood levels. Monitor lipid levels when starting Actemra.
Oral contraceptives
moderateCYP3A4 induction may potentially reduce hormonal contraceptive levels. Discuss with your doctor.
Methotrexate
minorCombination is approved and commonly used for RA. Requires continued monitoring of CBC and liver function tests.
Actemra (tocilizumab) is a highly effective biologic medication for rheumatoid arthritis, giant cell arteritis, and several other serious inflammatory and oncologic conditions. Its mechanism of action — blocking the IL-6 receptor — provides a targeted approach to reducing the chronic inflammation that drives these diseases, and clinical evidence shows it can meaningfully improve quality of life and prevent joint damage.
Supply has stabilized significantly since the 2021 COVID-19-driven shortage, and the availability of three FDA-approved biosimilars (Tofidence, Tyenne, and Avtozma) has expanded access and created cost-savings opportunities for patients and payers. The primary access challenges in 2026 are insurance-related: step therapy requirements, prior authorization delays, and cost-sharing for patients without manufacturer assistance programs.
If you're prescribed Actemra and struggling to find it or afford it, don't give up. Financial assistance programs can reduce your cost dramatically, and medfinder can help you quickly locate which pharmacies near you have it in stock. Work closely with your prescribing rheumatologist — they have the best relationships with specialty pharmacies and the most experience navigating the access barriers you may face.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
Real-time availability
Medfinder is actively checking pharmacy inventory for Actemra. We don't publish a number until we have enough verified pharmacy checks to be accurate — start a search and our team confirms current availability near you, usually within 24 hours.
ChatGPT
Claude
Gemini